Antikoagulantien und Thrombozytenaggregationshemmer

  • U. Schwabe

Zusammenfassung

Antikoagulantien und Thrombozytenaggregationshemmer werden in steigendem Umfang bei Thrombosen, Embolien und arteriellen Gefäßkrankheiten mit unterschiedlichen therapeutischen Schwerpunkten eingesetzt. Die akute Antikoagulation mit Heparin und die nachfolgende Gabe oraler Vitamin-K-Antagonisten ist die Standardtherapie für akute Venenthrombosen und Lungenembolien. Daneben werden orale Antikoagulantien zur Prophylaxe kardiogener Hirnembolien bei atrialen Thromben und bei arteriosklerotisch bedingten Karotisstenosen angewendet. Auch niedermolekulare Heparine werden zunehmend für die Therapie tiefer Venenthrombosen bei ambulanten Patienten eingesetzt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Antiplatelet Trialists’ Collaboration (1994): Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Brit. Med. J. 308: 81–106.CrossRefGoogle Scholar
  2. Bousser M. G., Eschwege E., Haguenau M., Lefauconnier J. M., Thibult N. et al. (1983): „AICLA“ controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 14: 5–14.PubMedCrossRefGoogle Scholar
  3. CAPRIE Steering Committee (1996): A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339.CrossRefGoogle Scholar
  4. Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. (1996): European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143: 1–13.PubMedCrossRefGoogle Scholar
  5. Gent M., Blakely J. A., Easton J. D., Ellis D. J., Hachinski V. C. et al. (1989): The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet I: 1215–1220.CrossRefGoogle Scholar
  6. Hass W. K., Easton J. D., Adams H. P. Jr., Pryse-Phillips W., Molony B. A. et al. (1989): A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N. Engl. J. Med. 321: 501–507.PubMedCrossRefGoogle Scholar
  7. Hirsh J., Levine M. N. (1992): Low molecular weight heparin. Blood 79: 1–17.PubMedGoogle Scholar
  8. Klimt C. R., Knatterud G. L., Stamler J., Meier P. (1986): Persantine-aspirin rein-farction study. Part II. Secondary coronary prevention with persantine and aspirin. J. Am. Coll. Cardiol. 7: 251–269.PubMedCrossRefGoogle Scholar
  9. Koopman M. M. W., Prandoni P., Piovella F., Ockelford P. A., Brandjes D. P. M. et al. (1996): Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N. Engl. J. Med. 334: 682–687.PubMedCrossRefGoogle Scholar
  10. Leizorovicz A., Haugh M. C., Chapuis F.-R., Samama M. M., Boissel J.-P. (1992): Low molecular weight heparin in prevention of perioperative thrombosis. Brit. Med. J. 305: 913–920.PubMedCrossRefGoogle Scholar
  11. Lensing A. W. A., Prins M. H., Davidson B. L., Hirsh J. (1995): Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch. Intern. Med. 155: 601–607.PubMedCrossRefGoogle Scholar
  12. Levine M., Gent M., Hirsh J., Leclerc J., Anderson D. et al. (1996): A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N. Engl. J. Med. 334: 677–681.PubMedCrossRefGoogle Scholar
  13. The Persantine-Aspirin Reinfaction Study Research Group (1980): Persantine and aspirin in coronary heart disease. Circulation 62: 449–461.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • U. Schwabe

There are no affiliations available

Personalised recommendations